Budesonide(Synonyms: 布地奈德)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Budesonide (Synonyms: 布地奈德) 纯度: 99.94%

Budesonide 是一种吸入型糖皮质类固醇，具有口服活性的糖皮质激素受体 (glucocorticoid receptor) 激动剂。Budesonide 可减少肺部肿瘤的大小，逆转 DNA 低度甲基化并调节基因的 mRNA 表达。Budesonide 是一种可以用于哮喘的抗炎药。

Budesonide(Synonyms: 布地奈德)

Budesonide Chemical Structure

CAS No. : 51333-22-3

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥512 In-stock
100 mg ￥465 In-stock
200 mg ￥860 In-stock
500 mg ￥1950 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Budesonide 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma[1][2][3].

体外研究
(In Vitro)

Budesonide is selective for human glucocorticoid receptor (hGR; EC50=45.7 pM) over mineralocorticoid receptors (EC50=7,620 pM) in CV-1 cells[1].
Budesonide (30 min prior to LPS) suppresses the activation of the NLRP3 inflammasome by LPS (100 ng/mL) plus ATP (5 mM) in macrophages (RAW 264.7 cells)[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Budesonide (2.0 mg/kg; orally via their diet; at 2, 7 and 21 days prior to killing) decreases the size of lung tumors[3].
Budesonide (0.5 mg/kg; intranasal administration 1 h before LPS injection (5 mg/kg)) pretreatment dramatically attenuates pathological injury and reduces pathological scores in mice with ALI in adult male C57BL/6 mice[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female strain A/J mice at 8 weeks of age[3]
Dosage: 2.0 mg/kg
Administration: Orally via their diet; at 2, 7 and 21 days prior to killing (27 weeks)
Result: Reduced the size of the lung tumors after 2 days and rapidly decreased the size of lung tumors, reversed DNA hypomethylation and modulated mRNA expression of genes.

Clinical Trial

分子量

430.53

Formula

C25H34O6
CAS 号

51333-22-3
中文名称

布地奈德；泼米考特得宝；拉埃诺考特
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 215 mg/mL (499.38 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3227 mL 11.6136 mL 23.2272 mL
5 mM 0.4645 mL 2.3227 mL 4.6454 mL
10 mM 0.2323 mL 1.1614 mL 2.3227 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.83 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.83 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.83 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Claudia Grossmann, et al. Transactivation via the Human Glucocorticoid and Mineralocorticoid Receptor by Therapeutically Used Steroids in CV-1 Cells: A Comparison of Their Glucocorticoid and Mineralocorticoid Properties. Eur J Endocrinol. 2004 Sep;151(3):397-406.

    [2]. Liang Dong, et al. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Immunol Res. 2019 Feb 27;2019:7264383.

    [3]. Michael A Pereira, et al. Modulation by Budesonide of DNA Methylation and mRNA Expression in Mouse Lung Tumors. Int J Cancer. 2007 Mar 1;120(5):1150-3.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务